Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 170 | 212 | 341 | 411 | 1,070 |
Receivables | 39 | 35 | 92 | 59 | 42 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 24 | 13 | 27 | 26 | 7 |
Other Current Assets | 4 | 3 | 5 | 4 | 5 |
Total Current Assets | 237 | 264 | 465 | 501 | 1,124 |
Net Property & Equipment | 16 | 12 | 21 | 14 | 7 |
Investments & Advances | 48 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 9 | 34 | 24 | 26 |
Intangibles | 470 | 458 | 742 | 796 | 326 |
Deposits & Other Assets | 6 | 5 | 3 | 4 | 2 |
Total Assets | 787 | 763 | 1,298 | 1,362 | 1,495 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 8 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 77 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 7 | 0 |
Accrued Expenses | 12 | 16 | 18 | 19 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 14 | 69 | 5 |
Total Current Liabilities | 17 | 99 | 42 | 100 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 33 | 31 | 59 | 65 | 33 |
Convertible Debt | 0 | 0 | 321 | 442 | 639 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 31 | 25 | 39 | 40 | 29 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 86 | 165 | 476 | 653 | 728 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 199 | 148 | 373 | 318 | 367 |
Retained Earnings | 503 | 451 | 449 | 392 | 400 |
Other Equity | -1 | -1 | -1 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 701 | 597 | 821 | 710 | 767 |
Total Liabilities & Shareholder's Equity | 787 | 763 | 1,298 | 1,362 | 1,495 |
Total Common Equity | 701 | 597 | 821 | 710 | 767 |
Shares Outstanding | 17.30 | 16.80 | 16.70 | 16.00 | 17.50 |
Book Value Per Share | 40.52 | 35.56 | 49.17 | 44.35 | 43.84 |
Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 311 | 170 | 191 | 219 |
Receivables | NA | 28 | 39 | 36 | 28 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 21 | 24 | 25 | 27 |
Other Current Assets | NA | 9 | 4 | 2 | 3 |
Total Current Assets | NA | 369 | 237 | 254 | 277 |
Net Property & Equipment | NA | 15 | 16 | 16 | 11 |
Investments & Advances | NA | 47 | 48 | 47 | 0 |
Other Non-Current Assets | NA | 66 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 9 | 9 |
Intangibles | NA | 397 | 470 | 425 | 442 |
Deposits & Other Assets | NA | 11 | 6 | 8 | 5 |
Total Assets | NA | 914 | 787 | 769 | 758 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 10 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 12 | 11 | 7 |
Income Taxes Payable | NA | 1 | 0 | 1 | 11 |
Other Current Liabilities | NA | 1 | 1 | 1 | 0 |
Total Current Liabilities | NA | 18 | 17 | 16 | 29 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 54 | 33 | 33 | 28 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 31 | 47 | 25 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 107 | 86 | 101 | 93 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 218 | 199 | 184 | 171 |
Retained Earnings | NA | 589 | 503 | 485 | 495 |
Other Equity | NA | -1 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 807 | 701 | 668 | 665 |
Total Liabilities & Shareholder's Equity | NA | 914 | 787 | 769 | 758 |
Total Common Equity | 0 | 807 | 701 | 668 | 665 |
Shares Outstanding | 18.00 | 17.70 | 17.30 | 17.30 | 17.20 |
Book Value Per Share | 0.00 | 45.57 | 40.52 | 38.61 | 38.66 |